

Micro- and Nano-Carriers for Treatment of Tuberculosis Lung Infections

Rachit Agarwal

Centre for BioSystems Science and Engineering

Indian Institute of Science



rachit@iisc.ac.in

<http://www.be.iisc.ac.in/~rachit/>

 @Rachit_Agarwal

Tuberculosis Lung infections

- Mycobacterium Tuberculosis (MTB) **infects nearly a third of human population**
- 10 million new TB cases each year
- 5% had **Multi-Drug Resistant (MDR) TB**
 - India has highest MDR cases in world
- **Total Drug Resistance (TDR) also reported in India**
 - Resistant against all clinically used antibiotics
- Long treatment: 6-12 months
- Macrophages uptake MTB but fail to fuse phagosome with lysosome
- Bacteria resides intracellularly and escapes lethal doses of traditional antibiotic treatment



Dry powder microparticle carrier for phage delivery


- Bacteriophage loaded on particles
- Dry powder formulations
- Deep lung delivery



Dry Powder Inhalers



● Carrier for deep lung delivery
★ Drug/Bacteriophage



Trachea

Bronchi


Bronchioles

Alveoli


Deep Lung Delivery

Overall system

Porous & hollow microparticles




Bacteriophages infecting bacteria



Treatment of MTB lung infections

- Co-delivery of porous and non-porous drug carriers to treat TB
- Effective against sensitive and drug resistant TB and also prevent its spread
- **Rapid translation** to clinics and **high patient compliance** with dry powder formulations



Major Techniques

- Mammalian and bacterial cell culture
- Engineering nano- and micro-carriers
- Characterization of charge and size (DLS, SEM etc.)
- Rodent and clinical samples handling
- Working in BioSafety Level-3 facilities

Further reading

Agarwal R, Johnson CT, Imhoff BR, Donlan RM, McCarty NA, García AJ. 2018. Inhaled bacteriophage-loaded polymeric microparticles ameliorate acute lung infections. *Nature Biomedical Engineering* 2:841-849.